Antibody Mediated Rejection clinical trials

Explore recruiting antibody mediated rejection clinical trials.

Recruiting antibody mediated rejection studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Antibody Mediated Rejection trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Global, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC Administered by a Prefilled Syringe in Kidney Transplant Recipients with Antibody Mediated Rejection.

Czechia, Spain, Belgium, Germany, France, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN2030 in Adult Patients with Antibody-Mediated Rejection after Kidney Transplantation

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Allogeneic adipose tissue-derived Mesenchymal stromal cells for the treatment of chronic-active antibody mediated rejection in Kidney transplant recipients

Denmark

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A multi-cohort, randomized, Phase 2, open-label study to assess the preliminary efficacy, safety, and pharmacokinetics of BIVV020 for prevention and treatment of antibody- mediated rejection in adult kidney transplant recipients

Sweden, Germany, Spain, France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601(siplizumab) Compared to Anti-Thymocyte Globulin (rATG), as Induction Therapy in de novo Renal Transplant Recipients

Sweden, Spain, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

Screening for subclinical antibody mediated rejection and efficacy of belatacept in the context of de novo donor specific antibody after kidney transplantation / BEL-AMR

France

Phase III and phase IV (Integrated) EU CTIS Study details

Antibody Mediated Rejection trials by city

Antibody Mediated Rejection in Toronto Antibody Mediated Rejection in Vancouver Antibody Mediated Rejection in Montreal Antibody Mediated Rejection in Calgary Antibody Mediated Rejection in Edmonton Antibody Mediated Rejection in Ottawa Antibody Mediated Rejection in Winnipeg Antibody Mediated Rejection in Quebec City Antibody Mediated Rejection in Hamilton Antibody Mediated Rejection in Kitchener Antibody Mediated Rejection in London Antibody Mediated Rejection in Halifax Antibody Mediated Rejection in New York Antibody Mediated Rejection in Los Angeles Antibody Mediated Rejection in Chicago Antibody Mediated Rejection in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease